Cancer Immunology, Immunotherapy

, Volume 53, Issue 3, pp 249–255

Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination

  • Pedro Romero
  • Jean-Charles Cerottini
  • Daniel E. Speiser
Review

DOI: 10.1007/s00262-003-0473-9

Cite this article as:
Romero, P., Cerottini, JC. & Speiser, D.E. Cancer Immunol Immunother (2004) 53: 249. doi:10.1007/s00262-003-0473-9

Abstract

Numerous phase I and II clinical trials testing the safety and immunogenicity of various peptide vaccine formulations based on CTL-defined tumor antigens in cancer patients have been reported during the last 7 years. While specific T-cell responses can be detected in a variable fraction of immunized patients, an even smaller but significant fraction of these patients have objective tumor responses. Efficient therapeutic vaccination should aim at boosting naturally occurring antitumor T- and B-cell responses and at sustaining a large number of tumor antigen specific and fully functional effector T cells at tumor sites. Recent progress in our ability to quantitatively and qualitatively monitor tumor antigen specific CD8 T-cell responses will greatly help in making rapid progress in this field.

Keywords

Cancer vaccinesTumor immunologyImmune monitoringTetramers

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Pedro Romero
    • 1
  • Jean-Charles Cerottini
    • 2
  • Daniel E. Speiser
    • 1
  1. 1.Divison of Clinical Onco-Immunology, Lausanne branch, University Hospital (CHUV)Ludwig Institute for Cancer ResearchLausanneSwitzerland
  2. 2.Lausanne BranchLudwig Institute for Cancer ResearchEpalingesSwitzerland